Vivos Therapeutics, Inc. reduced its outstanding debt by exchanging $2,861,270 in principal under a secured promissory note with Streeterville Capital, LLC for 11,445,080 shares of common stock at an exchange price of $0.25 per share, according to a corporate announcement released on September 8, 2026. The transaction, which took place on August 31, 2026, marks the latest step in a series of financial restructuring moves by the Littleton, Colorado-based medical device maker to satisfy Nasdaq listing requirements and enhance stockholders’ equity.
Debt Reduction and Balance Sheet Changes
The August 31 transaction follows an earlier exchange on August 4, 2026, in which Vivos traded $3,250,000 of principal under the Streeterville Note for 2,500 shares of Series B Non-Convertible Preferred Stock and 1,812,031 shares of common stock, as reported in company filings. According to Vivos, these combined agreements lowered the outstanding balance of the Streeterville Note to approximately $3.7 million as of August 31, 2026. That figure represents a significant drop from the note’s original principal amount of $8,225,000, which was established on June 9, 2025.
The company stated that the debt-for-equity exchanges are designed to reduce liabilities and correspondingly increase stockholders’ equity as the partitioned notes are surrendered and cancelled. The final financial impact of these transactions will appear in Vivos’ financial statements for the quarter in which each exchange settles.
Focus on Obstructive Sleep Apnea Treatment
Vivos Therapeutics, traded on the Nasdaq under the ticker VVOS, specializes in diagnostic and treatment methods for obstructive sleep apnea (OSA) and other sleep-related breathing disorders stemming from dentofacial abnormalities. The company manufactures FDA-cleared oral medical devices, including its flagship DNA appliance and Complete Airway Repositioning and Expansion (CARE) devices. Vivos’ devices are cleared by the U.S. Food and Drug Administration for adult patients across all severity levels of OSA, as well as for moderate-to-severe OSA in children aged 6 to 17.
According to data cited by the company, OSA affects an estimated one billion adults worldwide aged 30 to 69, though 80% or more remain undiagnosed. Vivos markets its nonsurgical, noninvasive, and nonpharmaceutical approach—known as The Vivos Method—as an alternative to legacy treatments like continuous positive airway pressure (CPAP) machines by targeting anatomical factors linked to the condition.
Keep reading